These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21221482)

  • 21. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
    Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
    Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.
    Martin AM; Krueger R; Almeida CA; Nolan D; Phillips E; Mallal S
    Pharmacogenet Genomics; 2006 May; 16(5):353-7. PubMed ID: 16609367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?
    Park WB; Choe PG; Song KH; Lee S; Jang HC; Jeon JH; Park SW; Park MH; Oh MD; Choe KW
    Clin Infect Dis; 2009 Feb; 48(3):365-7. PubMed ID: 19115972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [HLA-B*5701 and abacavir hypersensitivity reaction].
    Servonnet A; Leclercq E; Delacour H; Ceppa F
    Pathol Biol (Paris); 2010 Dec; 58(6):e95-100. PubMed ID: 19243901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
    Berka N; Gill JM; Liacini A; O'Bryan T; Khan FM
    Hum Immunol; 2012 Feb; 73(2):164-7. PubMed ID: 22197535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects.
    Orkin C; Sadiq ST; Rice L; Jackson F;
    HIV Med; 2010 Mar; 11(3):187-92. PubMed ID: 19780860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Flow cytometry analysis with a new FITC-conjugated monoclonal antibody-3E12 for HLA-B*57:01 rapid screening in prevention of abacavir hypersensitivity in HIV-1-infected patients.
    Rodríguez-Sáinz C; Valor L; Hernández DC; Gil J; Carbone J; Pascual-Bernaldez M; Rodríguez-Alcántara F; Martínez I; Vicario JL; Mallal S; Fernández-Cruz E
    HIV Clin Trials; 2013; 14(4):160-4. PubMed ID: 23924588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir.
    Agbaji OO; Akanbi MO; Otoh I; Agaba PA; Akinsola R; Okolie V; Ugoagwu PO; Babadoko AA; Adediran A; Finomo FO; Abah JO; Muktar HM; Akanmu AS
    Niger Postgrad Med J; 2019; 26(4):195-198. PubMed ID: 31621657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.
    Rodríguez-Nóvoa S; García-Gascó P; Blanco F; González-Pardo G; Castellares C; Moreno V; Jiménez-Nácher I; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1374-6. PubMed ID: 18184080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.
    Young B; Squires K; Patel P; Dejesus E; Bellos N; Berger D; Sutherland-Phillips DH; Liao Q; Shaefer M; Wannamaker P
    AIDS; 2008 Aug; 22(13):1673-5. PubMed ID: 18670229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA
    Mounzer K; Hsu R; Fusco JS; Brunet L; Henegar CE; Vannappagari V; Stainsby CM; Shaefer MS; Ragone L; Fusco GP
    AIDS Res Ther; 2019 Jan; 16(1):1. PubMed ID: 30651100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of two commercial real-time PCR assays for rapid screening of the HLA-B*57:01 allele in the HIV clinical laboratory.
    Avidor B; Girshengorn S; Giladi L; Israel S; Katz R; Turner D
    J Virol Methods; 2016 Nov; 237():18-24. PubMed ID: 27546346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abacavir hypersensitivity reaction.
    AIDS Patient Care STDS; 2002 May; 16(5):242. PubMed ID: 12058699
    [No Abstract]   [Full Text] [Related]  

  • 34. Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701.
    Rodríguez-Nóvoa S; Cuenca L; Morello J; Córdoba M; Blanco F; Jiménez-Nácher I; Soriano V
    J Antimicrob Chemother; 2010 Aug; 65(8):1567-9. PubMed ID: 20534626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prevalence of human leukocyte antigen (HLA)-B*57:01 in HIV-infected patients].
    Deveci A; Çoban AY; Durupınar B
    Mikrobiyol Bul; 2016 Oct; 50(4):544-551. PubMed ID: 28124959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of human leukocyte antigen-B*5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use.
    Puthanakit T; Bunupuradah T; Kosalaraksa P; Vibol U; Hansudewechakul R; Ubolyam S; Suwanlerk T; Kanjanavanit S; Ngampiyaskul C; Wongsawat J; Luesomboon W; Vonthanak S; Ananworanich J; Ruxrungtham K;
    Pediatr Infect Dis J; 2013 Mar; 32(3):252-3. PubMed ID: 22986704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance].
    Arnedo Valero M
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():34-9. PubMed ID: 18680694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
    Lucas A; Nolan D; Mallal S
    J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care.
    De Spiegelaere W; Philippé J; Vervisch K; Verhofstede C; Malatinkova E; Kiselinova M; Trypsteen W; Bonczkowski P; Vogelaers D; Callens S; Ruelle J; Kabeya K; De Wit S; Van Acker P; Van Sandt V; Emonds MP; Coucke P; Sermijn E; Vandekerckhove L
    PLoS One; 2015; 10(4):e0123525. PubMed ID: 25874872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.
    Kauf TL; Farkouh RA; Earnshaw SR; Watson ME; Maroudas P; Chambers MG
    Pharmacoeconomics; 2010; 28(11):1025-39. PubMed ID: 20575592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.